Publications by authors named "Mollie Moran"

16 Publications

Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists.

Authors:

Kristin L Koenig Ying Huang Emily K Dotson Shane Sheredy Seema A Bhat John C Byrd Emily Desmond Jill Ford Shauna Iarocci Jeffrey A Jones Margaret S Lucas Mollie E Moran Tracy E Wiczer Jennifer A Woyach Farrukh T Awan Kerry A Rogers

Blood Adv 2020 Oct;4(19):4860-4863

Division of Hematology and.

View Article and Find Full Text PDF

October 2020

Classic hairy cell leukemia complicated by pancytopenia and severe infection: a report of 3 cases treated with vemurafenib.

Authors:

Daniel P Shenoi Leslie A Andritsos James S Blachly Kerry A Rogers Mollie E Moran Mirela Anghelina Jeffrey A Jones Michael R Grever

Blood Adv 2019 01;3(2):116-118

Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH.

View Article and Find Full Text PDF

January 2019

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.

Authors:

Kerry A Rogers Ying Huang Amy S Ruppert Farrukh T Awan Nyla A Heerema Corinne Hoffman Gerard Lozanski Kami J Maddocks Mollie E Moran Mark A Reid Margaret Lucas Jennifer A Woyach W Thomas Whitlow Jeffrey A Jones John C Byrd

Blood 2018 10 15;132(15):1568-1572. Epub 2018 Aug 15.

Division of Hematology.

View Article and Find Full Text PDF

October 2018

New Treatment Paradigms Defined for Chronic Lymphocytic Leukemia.

Authors:

Mollie Moran Jeffrey Jones

J Adv Pract Oncol 2017 Apr 1;8(3):273-278. Epub 2017 Apr 1.

The James Cancer Hospital at The Ohio State University, Columbus, Ohio.

View Article and Find Full Text PDF

April 2017

Managing Infusion-Related Reactions for Patients With Chronic Lymphocytic Leukemia Receiving Obinutuzumab.

Authors:

Keith Dawson Mollie Moran Kathleen Guindon Hui Wan

Clin J Oncol Nurs 2016 Apr;20(2):E41-8

F. Hoffmann-La Roche Ltd.

View Article and Find Full Text PDF

April 2016

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders.

Authors:

Thomas S Lin Kristie A Blum Diane Beth Fischer Sarah M Mitchell Amy S Ruppert Pierluigi Porcu Eric H Kraut Robert A Baiocchi Mollie E Moran Amy J Johnson Larry J Schaaf Michael R Grever John C Byrd

J Clin Oncol 2010 Jan 14;28(3):418-23. Epub 2009 Dec 14.

Division of Hematology and Oncology, The Ohio State University, Center for Biostatistics, The Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

January 2010

Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia.

Authors:

Thomas S Lin Louie Naumovski Philip S Lecane Margaret S Lucas Mollie E Moran Carolyn Cheney David M Lucas See-Chun Phan Richard A Miller John C Byrd

Leuk Lymphoma 2009 Dec;50(12):1977-82

Division of Hematology-Oncology, The Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

December 2009

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease.

J Clin Oncol 2009 Dec 13;27(35):6012-8. Epub 2009 Oct 13.

Division of Hematology and Oncology, The Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

December 2009

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia.

Authors:

Mitch A Phelps Thomas S Lin Amy J Johnson Eunju Hurh Darlene M Rozewski Katherine L Farley Di Wu Kristie A Blum Beth Fischer Sarah M Mitchell Mollie E Moran Michelle Brooker-McEldowney Nyla A Heerema David Jarjoura Larry J Schaaf John C Byrd Michael R Grever James T Dalton

Blood 2009 Mar 3;113(12):2637-45. Epub 2008 Nov 3.

Comprehensive Cancer Center, College of Pharmacy, Division of Pharmaceutics, The Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

March 2009

Nursing guidelines for managing infections in patients with chronic lymphocytic leukemia.

Authors:

Mollie Moran Mary Browning Emma Buckby

Clin J Oncol Nurs 2007 Dec;11(6):914-24

James Cancer Hospital, Ohio State University, Columbus, Ohio, USA.

View Article and Find Full Text PDF

December 2007

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia.

Blood 2007 Jan 26;109(2):399-404. Epub 2006 Sep 26.

Division of Hematology-Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

January 2007

Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity.

Authors:

Guido Marcucci Wendy Stock Guowei Dai Rebecca B Klisovic Shujun Liu Marko I Klisovic William Blum Cheryl Kefauver Dorie A Sher Margaret Green Mollie Moran Kati Maharry Steven Novick Clara D Bloomfield James A Zwiebel Richard A Larson Michael R Grever Kenneth K Chan John C Byrd

J Clin Oncol 2005 May 11;23(15):3404-11. Epub 2005 Apr 11.

Division of Hematology-Oncology, The Comprehensive Cancer Center, The Ohio State University, 433A Starling-Loving Hall, 320 West 10th Ave, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

May 2005

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

Authors:

John C Byrd Guido Marcucci Mark R Parthun Jim J Xiao Rebecca B Klisovic Mollie Moran Thomas S Lin Shujun Liu Amy R Sklenar Melanie E Davis David M Lucas Beth Fischer Roshini Shank Sooraj L Tejaswi Philip Binkley John Wright Kenneth K Chan Michael R Grever

Blood 2005 Feb 5;105(3):959-67. Epub 2004 Oct 5.

Department of Internal Medicine, Division of Hematology-Oncology, Starling Loving Hall, Rm 302, The Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

February 2005

Antibody therapy for chronic lymphocytic leukemia: a promising new modality.

Authors:

Thomas S Lin Mollie Moran Margaret Lucas Sharon Waymer Sara Jefferson Diane B Fischer Michael R Grever John C Byrd

Hematol Oncol Clin North Am 2004 Aug;18(4):895-913, ix-x

Division of Hematology and Oncology, Starling Loving Hall, Room 302, The Arthur James Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

August 2004

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.

Authors:

Thomas S Lin Ian W Flinn Rama Modali Teresa A Lehman Jennifer Webb Sharon Waymer Mollie E Moran Margaret S Lucas Sherif S Farag John C Byrd

Blood 2005 Jan 24;105(1):289-91. Epub 2004 Jun 24.

Department of Medicine, Division of Hematology-Oncology, The Ohio State University, Columbus 43210, USA.

View Article and Find Full Text PDF

January 2005

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Authors:

Gerard Lozanski Nyla A Heerema Ian W Flinn Lisa Smith Jennifer Harbison Jennifer Webb Mollie Moran Margaret Lucas Thomas Lin Marcy L Hackbarth John H Proffitt David Lucas Michael R Grever John C Byrd

Blood 2004 May 15;103(9):3278-81. Epub 2004 Jan 15.

Department of Pathology, Ohio State University, Columbus, OH 43210, USA.

View Article and Find Full Text PDF

May 2004